MedPath

Artichoke and Bergamot Phytosome

Not Applicable
Completed
Conditions
Hypercholesterolemia
Interventions
Combination Product: Placebo
Dietary Supplement: Combined Bergamot phytosome and Artichoke leaf dry extract
Registration Number
NCT04697121
Lead Sponsor
Azienda di Servizi alla Persona di Pavia
Brief Summary

According to WHO data, about 50% of deaths each year are caused by cardiovascular disease. One of the strategies for prevention of cardiovascular diseases, in addition to a correct lifestyle, is to implement therapies that reduce the level of cholesterol in the blood and at the same time control the glycemic levels, which are closely related in the maintenance of metabolic homeostasis. The aim of this clinical study is to confirm the potential broader activity as hypocholesterolemic agent in bergamot poor-responders subjects with mild hypercholesterolemia. The study was a 8-week randomized double-blind placebo-controlled trial. Participants were randomized to either the supplement based on dry extract from artichoke leaf and bergamot phospholipid (31) or placebo arm (29).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • mild hypercholesterolemia (220 - 280 mg/dl)
  • subjects were not taking any medication likely to affect lipid metabolism (such as statins)
  • subjects were bergamot poor-responders
Exclusion Criteria
  • liver, renal and thyroid diseases
  • history of cardiovascular disease (CVD)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo-
Combined Bergamot Phytosome and Artichoke leaf dry extractCombined Bergamot phytosome and Artichoke leaf dry extract600 mg of Bergamot Phytosome and 100 mg of Artichoke leaf standardized dry extract
Primary Outcome Measures
NameTimeMethod
Changes of lipid parametersBaseline / 30 days / 60 days

Total cholesterol, LDL cholesterol, HDL cholesterol (mg/dl)

Secondary Outcome Measures
NameTimeMethod
Changes of lipid parametersBaseline / 30 days / 60 days

apolipoprotein A, apolipoprotein B, triglycerides (mg/dl)

Changes of anthropometric measurementsBaseline / 30 days / 60 days

waist circumference (cm)

Changes of metabolic parametersBaseline / 30 days / 60 days

Glycated Hemoglobin (percent)

Changes of body compositionBaseline / 30 days / 60 days

Fat mass (g), Fat Free Mass (g), Visceral Adipose Tissue (g)

Changes of safety parametersBaseline / 30 days / 60 days

Creatinine (mg/dl)

Trial Locations

Locations (1)

Azienda di Servizi alla Persona

🇮🇹

Pavia, Italy

© Copyright 2025. All Rights Reserved by MedPath